Related Experiment Video
Updated: Aug 18, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Multimodality approach towards advanced rectal carcinoma. "Its efficacy and safety"
1Department of Surgical Oncology, Henry Dunant Hospital, Athens, Greece. iasg@iasg.org
Background/Aims:
To evaluate the efficacy and safety of multimodality approach towards advanced rectal cancer.
Methodology:
In a prospective, randomized trial, two hundred and ten patients with advanced carcinoma of the rectum were studied. Patients were randomly divided in two groups A and B. Patients in group A underwent total mesorectal excision (TME) with adjuvant systemic chemotherapy and radiotherapy. Group B patients underwent TME with adjuvant stop-flow perfusion along with systemic chemotherapy
Results:
The five-year survival for Group A patients was 72% and for Group B patients the overall five-year survival was 92% and the disease-free survival was 87%.
Conclusions:
Multimodality approach to advanced rectal cancer leads to substantial prolongation of survival and optimization of quality of life.
